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Cross-sectional study (dataset 2) Longitudinal cohort study (dataset 4) 
HXB2 Amino Acid 
sequence Escape site  HLA matched 
with escape 
HLA mismatched 
with escape 
Estimated time 
to escape 
(years) 
Estimated time 
to reversion 
(years) 
HLA 
matched 
with escape 
HLA 
mismatched 
with escape 
Estimated time 
to escape 
(years) 
Estimated 
time to 
reversion 
(years) 
KIRLRPGGK K1, K9 4/14 7/32 23.9 No rev 3/14 2/38 10.5 36.4 
RLRPGGKKK K9 8/14 5/32 4.42 5.66 5/10 7/45 2.15 13.0 
GGKKKYKL K3, K5, K7 6/7 28/39 1.64 No rev 2/7 4/101 4.13 >50 
KYKLKHIVW K1, K3, I7 8/9 26/37 1.76 No rev 5/5 4/106 0.75 >50 
GSEELRSLY L5, R6, Y9 10/11 24/35 1.73 >50 4/7 2/91 2.38 >50 
SLYNTVATL Y3, N4, T5, V6, T8 8/14 19/32 14.7 No rev 2/25 3/55 27.8 34.2 
AADTGHSNQ A1, G5, N6, S7, S8, Q9 HLA restriction not defined 
HSNQVSQNYP N1, S2, S3, Q4, V5 HLA restriction not defined 
ISPRTLNAW A(-1), I1 6/8 21/39 1.75 No rev 3/5 4/75 1.92 37.7 
KAFSPEVIPMF A2 0/10 5/66 >50 No rev 1/9 0/6 16.0 No rev 
EVIPMFSAL E1, S7 1/4 16/72 16.6 No rev 1/4 0/43 6.75 No rev 
TSTLQEQIGW T3 10/15 4/61 2.04 3.78 4/6 7/12 1.56 2.50 
KRWIILGLNK R2 3/9 3/67 8.28 7.37 3/17 1/9 11.1 14.5 
NANPDCKTI A2, T8 2/11 13/65 29.6 No rev 0/9 2/30 No esc 29.8 
DCKTILKAL K3 2/14 1/62 26.3 3.00 0/35 0/1 No esc No rev 
CGKEGHTAR R9 No sequence No sequence 
GPKVKQWPL K3 1/8 4/45 48.5 No rev 0/12 0/8 No esc No rev 
TAFTIPSI I8 7/8 20/55 0.93 25.2 1/1 2/28 0.50 24.6 
AIFQSSMTK A1, F3, Q4 2/22 1/41 >50 3.66 0/22 0/2 No esc No rev 
IVLPEKDSW V2, D7 4/6 19/55 2.58 No rev 1/1 0/30 0.50 No rev 
IPLTEEAEL E5 No sequence 0/1 1/21 No esc 37.5 
ETFYVDGAANR F3, D6 0/3 0/71 No esc Indeterminate No sequence 
QVPLRPMTYK V2, L4, R5, M7, T8 0/13 2/38 >50 No rev 2/21 5/11 18.4 1.85 
VPLRPMTY T7, Y8 3/7 2/44 6.18 2.02 3/9 4/18 4.50 6.00 
RPMTYKAAV T4, Y5 1/5 4/46 26.2 25.2 2/18 2/16 16.4 12.4 
KAAVDLSHF A2 4/8 21/43 6.25 No rev 1/2 7/58 3.50 14.0 
FLKEKGGL L2, K3, E4, K5 4/8 12/43 7.83 No rev -/0 0/88 Indeterminate No rev 
HTQGYFPDW H1 6/6 11/45 0.00 27.7 2/5 0/32 2.25 No rev 
TPGPGVRYPL P2 0/5 1/46 >50 No rev 1/22 1/5 34.5 9.00 
RYPLTFGWCY Y2 12/14 7/37 0.89 4.83 5/11 5/18 1.85 6.65 
SRLAFHHVAR R10 No sequence 1/3 4/45 3.50 14.7 
 
 Table S2.   A summary of escape and reversion data from the cross-sectional study (dataset 2) and the longitudinal cohort study (dataset 
4). 
This is a summary of escape and reversion data relating to 31 epitopes with described escape mutants in HIV-1 gag, RT and nef. Sequence data 
from other HIV genes were not yet available from either of these studies. These are the same epitopes (in the same order) as provided in Table 
S1. In this analysis any mutation in any of the previously defined escape sites within an epitope (Table S1) was counted as an escape mutant. 
The prevalence of escape in HLA matched and HLA mismatched hosts in the cross-sectional data are provided here in columns 3 and 4 and also 
in Fig. 2B. Escape and reversion rates estimated from these data using the mathematical model are presented in columns 5-8. Model estimates 
assume that 0.3cβ =  (i.e. 0 3R =  if 0.1μ α+ = ), that the epidemic duration is 27 years (t=27) and that the proportion of hosts in the population 
with each HLA is as presented in Table S1. The escape rate estimates in columns 5 and 9 are compared in Fig. 3A. Likewise, the reversion rate 
estimates in columns 6 and 10 are compared in Fig. 3B. 
